ストックスクリーナーアプリを入手
2.78
4.79%
-0.14
アフターアワーズ：
2.75
-0.03
-1.08%
前日終値:
$2.92
開ける：
$2.93
24時間の取引高:
75,212
Relative Volume:
0.30
時価総額：
$3.67M
収益：
-
当期純損益:
$-23.42M
株価収益率:
-0.0356
EPS:
-78
ネットキャッシュフロー:
$-16.67M
1週間 パフォーマンス:
-35.65%
1か月 パフォーマンス:
-74.73%
6か月 パフォーマンス:
-81.77%
1年 パフォーマンス:
-95.76%
1日の値動き範囲:
$2.71
$3.05
1週間の範囲:
$2.71
$4.28
52週間の値動き範囲:
$2.71
$74.50
Mustang Bio Inc Stock (MBIO) Company Profile
MBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
2.78 | 3.67M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-10-02 | 開始されました | B. Riley FBR | Buy |
| 2019-11-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-08-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Mustang Bio Inc (MBIO) 最新ニュース
Mustang Bio sets terms for $8M public offering - MSN
Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewswire
Mustang Bio Announces Pricing of $8 Million Public Offering - Benzinga
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - StockTitan
Mustang Bio says it needs additional funds to avoid bankruptcy - The Business Journals
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Mustang Bio stock plunges to 52-week low of $4 - MSN
Mustang Bio (MBIO) Stock Price, News & Analysis - MarketBeat
Stock market today: VerifyMe -14.42%, PTL -13.23% among biggest losers in early trading - Business Upturn
Mustang Bio Inc. Appoints Michael J. Zelefsky as Director -June 13, 2017 at 04:02 pm EDT - Marketscreener.com
Mustang Bio, Inc. Announces Management Changes -April 24, 2017 at 08:00 am EDT - Marketscreener.com
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer -December 12, 2023 at 06:23 am EST - Marketscreener.com
Mustang Bio, Inc. Terminates Exclusive License Agreement with Regents of the University of California - Marketscreener.com
UBriGene Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc. - Marketscreener.com
Mustang Bio, Inc. Announces CFO Changes -November 15, 2024 at 04:50 pm EST - Marketscreener.com
Mustang Bio stock plunges to 52-week low of $0.13 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $0.13 - Investing.com
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Mustang Bio announces 1-for-50 reverse stock split By Investing.com - Investing.com Nigeria
Dow Gains Over 200 Points; Signet Jewelers Shares Plunge - Benzinga
Mustang Bio Lauds New Stock Split - Baystreet.ca
Mustang Bio announces 1-for-50 reverse stock split - Investing.com India
Mustang Bio secures shareholder nod for major stock issuance By Investing.com - Investing.com Nigeria
Mustang Bio secures shareholder nod for major stock issuance - Investing.com India
Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off - MSN
Fortress Biotech subsidiary's drug application accepted by FDA - Investing.com
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Stock market news: Neumora Therapeutics down by 80.75% while N2OFF surged by 333.47% during mid day trading - Business Upturn
Wall Street Today: US stocks open higher after markets reopen post New Year; Tesla shares down 7% on low delivery data | Stock Market News - Mint
Mustang Bio files to sell 34.77M shares of common stock for holders - MSN
Mustang Bio Inc Still Hasn’t Convinced Analysts? - Stocks Register
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Likelihood of Approval and Phase Transition Success Rate ModelMB-108 in Recurrent Malignant Glioma - GlobalData
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Mustang Bio faces delisting, appoints new interim CFO - Investing.com
Mustang Bio's Interim CFO Resigns After 10 Months - MarketWatch
Mustang Bio Faces Nasdaq Delisting and Leadership Changes - TipRanks
Mustang Bio, Inc. Announces CFO Changes - Marketscreener.com
ARMISTICE CAPITAL, LLC Acquires New Stake in Mustang Bio Inc - GuruFocus.com
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Crude Oil Brent (F) (QAX25) Quote - The Globe and Mail
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Inc (MBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
大文字化:
|
ボリューム (24 時間):